[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634445":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":56,"collaborators":24,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":24,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":24,"studyType":71,"phases":72,"briefSummary":75,"conditions":76,"keywords":24,"overallStatus":80,"whyStopped":24,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Luspatercept group","EXPERIMENTAL","Luspatercept",[13],"Drug: Luspatercept",{"label":15,"type":6,"description":16,"interventionNames":17},"Control group","Control",[18],"Other: Control",[20,25],{"type":21,"name":11,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","On the 7th day after allo-HSCT, the first dose of Luspatercept 1.0mg\u002Fkg was administered subcutaneously. If the peripheral blood HGB was \\\u003C 70g\u002FL on the 21st day after allo-HSCT, the second dose of Luspatercept 1.0mg\u002Fkg was given subcutaneously; if the peripheral blood HGB was ≥ 70g\u002FL on the 21st day after allo-HSCT, no second dose of Luspatercept subcutaneous injection was given.",[9],null,{"type":6,"name":16,"description":26,"armGroupLabels":27,"otherNames":24},"The patient will receive the best supportive treatment including blood transfusion.",[15],[29],{"name":30,"affiliation":5,"role":31},"Qifa Liu","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Li Xuan","CONTACT","+86-020-61641613","18956985366@163.com",{"name":30,"role":35,"phone":39,"phoneExt":24,"email":40},"+86-020-62787883","liuqifa628@163.com",[42],{"facility":5,"status":24,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Guangzhou","Guangdong","510515","China","CN",{"type":49,"coordinates":50},"Point",[51,52],113.25,23.11667,{"lat":52,"lon":51},[55],{"name":30,"role":35,"phone":39,"phoneExt":24,"email":40},{"type":57,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100634445","phase-2-luspatercept-in-preventing-poor-erythroid-engraftment-for-hematological-malignancies-with-moderate-to-severe-myelofibrosis-100634445",false,"NCT07539779","Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis","The Efficacy and Safety of Luspatercept in Preventing Poor Erythroid Engraftment After Allo-HSCT for Hematological Malignancies With Moderate to Severe Myelofibrosis: A Prospective, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18-65 years old, gender not restricted;\n* ECOG score 0-2 points;\n* Hematological malignancies with moderate to severe myelofibrosis\n* Willing to undergo the first allo-HSCT with a suitable donor\n* In a CR state before transplantation.\n\nExclusion Criteria:\n\n* Has previously undergone allo-HSCT;\n* ECOG score is 3-5;\n* Expected lifespan after transplantation is less than 30 days;\n* Has severe cardiac dysfunction, severe arrhythmia or severe pulmonary dysfunction (obstructive and\u002For restrictive ventilation disorder);\n* Has severe liver dysfunction, with liver function indicators (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL)) more than twice the upper limit of normal;\n* Has severe renal dysfunction, with creatinine (Cr) more than twice the upper limit of normal or 24-hour creatinine clearance rate (Ccr) lower than 30 ml\u002Fmin;\n* Has severe active bleeding;\n* Patients judged by the investigator to be unsuitable for participating in this trial.","ALL","18 Years","65 Years",{"count":69,"type":70},196,"ESTIMATED","INTERVENTIONAL",[73,74],"PHASE2","PHASE3","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with moderate to severe myelofibrosis (MF). Currently, there is a lack of effective prevention strategies for poor erythroid engraftment after transplantation. Luspatercept, a novel TGF-β superfamily signaling pathway modulator, has shown potential in small-sample studies for the treatment and prevention of post-transplant anemia. Given the high proportion and poor prognosis of poor engraftment function in hematological malignancies with moderate to severe myelofibrosis after transplantation, we plan to conduct a prospective, multicenter, randomized controlled study to explore the efficacy and safety of luspatercept in preventing poor erythroid engraftment after allo-HSCT in hematological malignancies with moderate to severe myelofibrosis.",[11,77,78,79],"Poor Erythroid Engraftment","Hematological Malignancies","Myelofibrosis (MF)","NOT_YET_RECRUITING","2026-04-13",{"date":83,"type":84},"2026-04-20","ACTUAL",{"date":86,"type":70},"2026-05-01",{"date":88,"type":70},"2030-12-31",{"name":5,"class":6},1]